PDCD1 and cancer: When T cells are activated, the second immune checkpoint PD-1 inhibits T cell activation and inflammatory factor production by binding to its ligands PD-L1 and PD-L2 leading to dephosphorylation of CD28, while cancer cells usually overexpress PD-L1 to escape (Ai et al., 2020).